
Phreesia Inc (PHR) Stock Forecast & Price Target
Phreesia Inc (PHR) Analyst Ratings
Bulls say
Phreesia is fairly valued at its current levels with a CY27E EV/adjusted EBITDA multiple of 3.8x and a CY27E EV/FCF multiple of 9.1x. While the company's 15.9% Y/Y revenue growth in Q4F26 was above expectations, uncertainty around future growth rates and macroeconomic and competitive headwinds justify the discount to the peer group median. Furthermore, its heavy reliance on payment processing fees, which make up 37% of its revenue, leaves it vulnerable to any decline in patient visit volumes due to a potential future surge in COVID-19 cases.
Bears say
Phreesia is expected to face significant challenges in the coming years as they are experiencing stagnant growth in their largest revenue line and increasing competition for lower healthcare ad budgets. Additionally, the company's recent acquisition of AccessOne is not performing as well as expected and is heavily reliant on a few key clients. The company also faces risks in terms of changing regulations and potential privacy and security breaches. These challenges are expected to dampen the company's growth and profitability, causing concern for investors and leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.
Phreesia Inc (PHR) Analyst Forecast & Price Prediction
Start investing in Phreesia Inc (PHR)
Order type
Buy in
Order amount
Est. shares
0 shares